The ability to achieve efficient and selective transformations for the formation of carbon-carbon and carbon-heteroatom bonds is the primary goal of the research described in our parent grant (GM122483). We seek to develop new transition metal-catalyzed methods that are general, user-friendly, and have a significant impact on the field of organic synthesis, particularly in pharmaceutical research. Our current work involves palladium-catalyzed cross coupling for C?N, C?O and C?F bonds and copper-catalyzed processes for the regio- and enantioselective construction of C?N and C?C bonds. In the development of new methods, we try to explore diverse substrate scopes to understand the applicability and generality of these protocols. On average, our published methods each have >20 substrates, we detail the isolated yields of at least two independent experiments to ensure reproducibility and the compounds are purified by flash column chromatography. We are seeking to update and replace our automated chromatography system due to the age of our current equipment (6 and 9 years old) and the number of researchers (33 users) that rely on the system on a daily basis for the purification and isolation of compounds. A new automated system would increase efficiency (2-3 times faster than manual chromatography), decrease solvent waste (environmentally friendly), and have improved reliability (current equipment has had extensive downtime due to repairs). This would greatly facilitate our research efforts in the development and optimization of new methods of C? C and C?X bond formations.
The chemistry we are proposing will improve access to compounds of importance in biomedical research in both academia and industry. The methods we have developed for carbon-heteroatom and carbon-carbon bond formation are regularly used by those in discovery and process groups in the pharmaceutical industry for the preparation of new biologically relevant compounds. The methods we are devising will allow for the construction of analogues with increased potency and reduced side effects. (This is the same project narrative from the parent grant for R35GM122483)
Showing the most recent 10 out of 18 publications
